Report Type : Therapy Reports
Report Category : Cardiovascular
Report Subcategory : Pulmonary Arterial Hypertension
Price : 2999.00
Date : February 2023
Pulmonary Arterial Hypertension : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing
Pulmonary artery hypertension (PAH):
Pulmonary artery hypertension (PAH) is a serious condition that occurs when the blood pressure in the arteries of the lungs is higher than normal. It can be caused by the narrowing and thickening of the small arteries in the lungs, which blocks blood flow and makes the heart work harder to pump blood.
Pulmonary arterial hypertension (PAH) is a rare disease with an estimated prevalence of 15–50 cases per million people. The incidence and prevalence of PAH are increasing, likely due to a number of factors, including: Heightened awareness, Increased access to echocardiograms and right heart catheter studies, and An aging population.
Here are some other facts about PAH:
Causes
PAH can be caused by a number of things, including idiopathic, heritable, drug-induced, and connective tissue disease– and congenital heart disease–associated causes. Rarer causes include HIV, schistosomiasis, and portal hypertension.
Sex
Women are more likely to have PAH, with registries reporting a 65–80% female predominance of the disease.
Age
The mean age of diagnosis of PAH is in the fifties, with more than 25% of patients being over 70 years.
Survival
Median survival rates have improved dramatically over the past two decades.
Management
Treatment for PAH is based on treating the underlying cause and alleviating symptoms. Treatment options include vasodilator agents, interventional and surgical options, and lung transplantation.
Top 50 Key Players:
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Bayer AG
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Bristol-Myers Squibb Co
Gilead Sciences Inc
Eli Lilly and Co
Boehringer Ingelheim International GmbH
Biogen Inc
Chiesi Farmaceutici SpA
United Therapeutics Corp
Mochida Pharmaceutical Co Ltd
Handok Inc
Lee's Pharmaceutical Holdings Ltd
Minapharm Pharmaceuticals & Chemical Industries
Insys Therapeutics Inc
Acceleron Pharma Inc
Correvio Pharma Corp
Reata Pharmaceuticals Inc
Cipher Pharmaceuticals Inc
C4X Discovery Holdings Plc
Mezzion Pharma Co Ltd
AVEO Oncology Inc
Anterogen Co Ltd
SteadyMed Ltd
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Actelion Pharmaceuticals Ltd
Janssen Global Services LLC
APT Therapeutics Inc
Northern Therapeutics Inc
AVEO Pharmaceuticals Inc
Aqualung Therapeutics Corp
Gmax Biopharm Ltd
Galectin Therapeutics Inc
GenThera Inc
Excubio Pharmaceuticals Inc
Morphogen-IX Ltd
Abivax SA
Reviva Pharmaceuticals Inc
Complexa Inc
Aerogen Ltd
Government Japan
Gossamer Bio Inc
Roivant Sciences Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Sandberg Development AB
Respira Therapeutics Inc
